



PP2

Catal	oa	No:	tcsc1	663
Cata.	. – –	•••		

Available Sizes
Size: 5mg
Size: 10mg
Size: 50mg
Size: 100mg
Specifications
CAS No: 172889-27-9
Formula: C ₁₅ H ₁₆ CIN ₅
Pathway: Protein Tyrosine Kinase/RTK
Target: Src
Purity / Grade: >98%
Solubility: H2O :
Alternative Names: AGL 1879
Observed Molecular Weight: 301.77





Product Description

PP2 is a potent, reversible, ATP-competitive, and selective inhibitor of the **Src** family of protein tyrosine kinases with **IC**₅₀s of 4 and 5 nM for **Lck** and **Fyn**, respectively.

IC50 & Target: IC50: 4 nM (Lck), 5 nM (Fyn)^[1]

In Vitro: At 10 μ M, the effect of PP2 on cellular proliferation is not significant, indicating that, at this low concentration, the effect of PP2 on Gemcitabine cytotoxicity does not simply reflect a direct antiproliferative effect, but rather a potentiation of Gemcitabine-induced cytotoxicity. Above 20 μ M, growth is increasingly suppressed, a finding consistent with reports in other human cancer cell lines. Although 10 μ M PP2 is used in our study, at higher concentrations PP2 is reported to inhibit other intracellular kinases^[2]. PP2 is the most widely used commercially available Src family kinase inhibitor. PP2 inhibits Src family kinase activity with IC₅₀ of ~5 nM in vitro, concentrations to 10 μ M are often necessary to achieve complete Src family kinase inhibition in cell culture^[3].

In Vivo: The tumor growth inhibition rate is 25% in the PP2 treatment group and 5% in the Gemcitabine treatment group (P>0.05). When administered in combination, PP2 and Gemcitabine produce a tumor growth inhibition rate of 98% (P[2].

$$H_2N$$
 N
 N
 N
 N

All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!